Lung Disease, Pulmonary Fibrosis
Conditions
Keywords
COPD, Smoking, Idiopathic Pulmonary Fibrosis, Natural History
Brief summary
Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta \<=1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.
Detailed description
Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.
Interventions
None listed
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: For subjects with lung diseases: * Men and women age 40-80 years * Smokers with greater than or equal to 10 pack-year history of ever-smoking
Exclusion criteria
For subjects with lung diseases: Subjects will be excluded from the study if they meet one or more of the following criteria: * Subjects who are under the age of 40 or over 80 years old * Women who are pregnant or lactating * Have known allergies to lidocaine or medications used for moderate sedation * Active coronary artery disease * Cerebral-vascular accident within the past 12 months * Active anticoagulation * Active infections * Cancer, or a history of cancer within the previous 5 years of screening (other than adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or carcinoma in situ of the uterine cervix with no evidence of recurrence). * Poorly controlled chronic diseases * Unable to provide consent * Impaired renal function (including dialysis) * Contraindications to MRI scan including: * electrical implants such as cardiac pacemakers or perfusion pumps * ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants * ferromagnetic objects such as jewelry or metal clips in clothing * pre-existing medical conditions, including a likelihood of developing seizures or anxiety disorders such as claustrophobia, panic attacks or any psychiatric disorder INCLUSION CRITERIA: For Non-Smoking Controls * Men and women age 40-80 years * No prior history of smoking (this is a non-smoking cohort)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD. | 3 years | Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD |
Countries
United States
Outcome results
None listed